CSF inflammatory cytokines and correlation with clinical features in early, untreated PD patients
Objective: The aims of the present study were to investigate the levels of inflammatory cytokines in the cerebrospinal fluid (CSF) of drug-naïve Parkinson's Disease (PD)…Intestinal Methanogen Overgrowth (IMO) More Prevalent than SIBO in Parkinson’s disease with Constipation: Preliminary Results
Objective: Our aim is to quantify the prevalence of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) in PD subjects with constipation compared…Urinary Symptoms and Parkinson’s Disease: The Patient’s Perspective
Objective: To learn about prevalence rates and the impact of urinary symptoms on day-to-day function and quality of life from the patient’s perspective. Background: Urinary…Movement Disorders After Bariatric Surgeries – Case Series
Objective: Our objective is to report 6 cases series of MD after Bariatric surgeries (BS) and one case after hiatal surgery, with BS behavior. Background:…Premotor compensatory mechanisms in Parkinson’s disease with LRRK2-R1441H mutation
Objective: To investigate the time course of modifications in dopaminergic terminals during the premotor phase in LRRK2 genetically determined Parkinson’s disease (PD). Background: Increased dopamine…Video-to-Home Cognitive-Behavioral Therapy for Veterans with Depression and Parkinson’s Disease: A Randomized Controlled Trial
Objective: For the nearly 100,000 veterans with Parkinson’s disease (PD) receiving Veterans Affairs (VA) health care, depression is prevalent, yet often undiagnosed or undertreated. This…Mental Health Matters Too – Integration of physical and mental health in a multidisciplinary Parkinson’s Clinic
Objective: The overall aim of the project was to demonstrate that people with Parkinson’s disease benefit from good mental health care when mental health services…Effect of Combined Modality Treatment on Sustained Phonation in Parkinson’s Disease
Objective: To determine whether Lee Silverman Voice Treatment (LSVT-LOUD(R)) combined with Transcranial Magnetic Stimulation in individuals with Parkinson's disease (PD) improves phonation to a greater…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period
Objective: To test if intermittent intraputamenal monthly infusions of CDNF have an effect on striatal dopamine transporter (DAT) binding, as measured by PET, in subjects…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »